

Supplementary Material

Search strategy (August 31, 2021)

Search strategy for Embase (934 items)

1. 'coronavirus disease 2019'/exp OR 'Severe acute respiratory syndrome coronavirus 2'/exp OR (COVID-19 OR SARS-CoV-2):ti,ab
2. vaccine/exp OR vaccination/exp OR immunization/exp OR (vaccin* OR immuniz*):ti,ab
3. (variant* OR B.1.1.7 OR B.1.351 OR P.1 OR B.1.617.2):ti,ab
4. #1 AND #2 AND #3

Search strategy for Pubmed (1203 items)

1. COVID-19[Mesh] OR SARS-CoV-2[Mesh] OR "COVID-19 Vaccines"[Mesh] OR COVID-19[Title/Abstract] OR SARS-CoV-2[Title/Abstract]
2. vaccines[Mesh] OR vaccination[Mesh] OR immunization[Mesh] OR vaccin*[Title/Abstract] OR immuniz*[Title/Abstract]
3. variant*[Title/Abstract] OR B.1.1.7[Title/Abstract] OR B.1.351[Title/Abstract] OR P.1[Title/Abstract] OR B.1.617.2[Title/Abstract]
4. #1 OR #2 OR #3

Search strategy for Cochrane Library (23 items)

1. [mh COVID-19]
2. [mh SARS-CoV-2]
3. COVID-19:ti,ab
4. SARS-CoV-2:ti,ab
5. #1 OR #2 OR #3 OR #4
6. [mh vaccines]
7. [mh vaccination]
8. [mh immunization]
9. vaccin*:ti,ab
10. immuniz*:ti,ab
11. #6 OR #7 OR #8 OR #9 OR #10
12. (variant* OR B.1.1.7 OR B.1.351 OR P.1 OR B.1.617.2):ti,ab
13. #5 AND #11 AND #12


Search strategy for Clinicaltrial.gov (66 items)

(vaccines OR vaccine OR vaccination OR immunization) AND (variant OR variants) AND (COVID-19 OR SARS-CoV-2)

Search strategy for medRxiv (596 items)

(vaccin*) AND (variant*) AND (COVID-19 OR SARS-CoV-2) AND (Efficacy OR Effectiveness)

Supplementary Figure



Supplementary Figure 1. Flow chart of literature search and study selection.

Supplementary Tables

Supplementary Table 1. Risk of bias for included RCTs

Study (First author)	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall bias
Heath	Low	Some concerns	Some concerns	Low	Some concerns	Some concerns
Emary	Low	Some concerns	Some concerns	Low	Some concerns	Some concerns
Shinde	Low	Low	Some concerns	Low	Some concerns	Some concerns
Madhi	Low	Some concerns	Low	Low	Some concerns	Some concerns
Sadoff	Low	Some concerns	Some concerns	Low	Low	Some concerns
Thomas (preprint)	Low	Some concerns	Low	Low	Low	Some concerns
Ella (preprint)	Low	Some concerns	Some concerns	Low	Low	Some concerns

Supplementary Table 2. Risk of bias for included cohort studies

	Selection				Comparability	Exposure			Total score	Quality
	Item 1	Item 2	Item 3	Item 4	Item 5	Item 6	Item 7	Item 7		
Hall	1	1	1	1	1	1	1	1	8	Good
Haas	1	1	1	0	1	1	1	1	7	Good
Lumley	1	1	1	0	1	1	1	1	7	Good
Williams	0	1	1	0	0	0	1	1	4	Moderate
Nanduri	1	1	1	0	1	1	1	1	7	Good
Fowlkes	0	1	1	0	1	0	1	1	5	Moderate
Puranik (preprint)	1	1	1	0	2	1	1	1	8	Good
Lefèvre (preprint)	0	1	1	0	1	1	1	1	6	Moderate
Dagan	1	1	1	0	2	1	1	1	8	Good
Pouwels (preprint)	1	1	1	0	2	1	1	1	8	Good

Item 1: Representativeness of the exposed cohort.

Item 2: Selection of the non-exposed cohort.

Item 3: Ascertainment of exposure.

Item 4: Demonstration that outcome of interest was not present at start of study.

Item 5: Comparability of cohorts on the basis of the design or analysis.

Item 6: Assessment of outcome.

Item 7: Was follow up long enough for outcomes to occur.

Item 8: Adequacy of follow up of cohorts.

Supplementary Table 3. Risk of bias for included case-control studies

	Selection				Comparability Item 5	Exposure			Total score	Quality
	Item 1	Item 2	Item 3	Item 4		Item 6	Item 7	Item 7		
Charmet	1	1	1	1	1	1	0	1	7	Good
Nasreen (preprint)	1	1	1	1	1	1	1	1	8	Good
Skowronski	1	0	1	1	1	1	1	1	7	Good
Hitchings (preprint)	1	0	1	1	0	1	1	1	6	Moderate
Ranzani	1	0	1	1	2	1	1	1	8	Good
Lopez Bernal	1	1	1	1	2	1	1	1	9	Good
Tang (preprint)	1	1	1	1	2	1	1	1	9	Good
Li	1	0	1	1	1	1	1	1	7	Good
Abu-Raddad	1	1	1	1	2	1	1	1	9	Good
Sheikh	1	0	1	1	0	1	1	1	6	Moderate
Chemaitelly	1	1	1	1	2	1	1	1	9	Good
Bernal	1	0	1	1	1	1	1	1	7	Good
Chung	1	1	1	1	1	1	1	1	8	Good
Carazo	1	0	1	1	1	1	1	1	7	Good
Chemaitelly (preprint)	1	1	1	1	2	1	1	1	9	Good
Pramod (preprint)	1	0	1	1	1	1	1	0	6	Moderate

Item 1: Is the case definition adequate?

Item 2: Representativeness of the cases.

Item 3: Selection of controls.

Item 4: Definition of controls.

Item 5: Comparability of cases and controls on the basis of the design or analysis.

Item 6: Ascertainment of exposure.

Item 7: Same method of ascertainment for cases and controls.

Item 8: Non-Response Rate.

Supplementary Table 4. VE of COVID-19 vaccines against B.1.1.7 (Alpha) variant

First author/Country	Study design	Vaccine/control Cases/controls	or	Participants	Age (years)	Vaccine	Outcomes	Day_1	VE% of one dose (95% CI)	Day_2	VE% of two doses (95% CI)	Variants
Heath/UK	RCT	7,020/7,020		GP	18-84	NVX-CoV2373	Symptomatic	NA	NA	7	86.3 (71.3–93.5)	Alpha
Emary/UK	RCT	4,244/4,290		GP	≥18	ChAdOx1	Symptomatic	NA	NA	14	70.4 (43.6–84.5)	Alpha
Hall/UK	Cohort	8,203/15,121		HCWs	≥18	BNT162b2	All infections	21	72.0 (58.0–86.0)	7	86.0 (76.0–97.0)	Alpha (>50%)
Haas/Israel	Cohort	4,714,932/1,823,979		GP	≥16	BNT162b2	All infections	NA	NA	7	96.5 (96.3–96.8)	Alpha (95%)
Lumley/UK	Cohort	10,651/10,513		HCWs	39 (30-50) ¹	BNT162b2/ ChAdOx1	All infections	14	21.0 (-3.0–39.0)	14	82.0 (27.0–95.0)	Alpha (51%)
Dagan/Israel	Cohort	596,618/596,618		GP	≥16	BNT162b2	All infections	14-21	46.0 (40.0–51.0)	7	92.0 (88.0–95.0)	Alpha (80%)
Pouwels/UK	Cohort	384,543 (total)		GP	≥18	BNT162b2	All infections	21	59.0 (52.0–65.0)	14	78.0 (68.0–84.0)	Alpha
	<i>_preprint</i>			GP	≥18	ChAdOx1	All infections	21	63.0 (55.0–69.0)	14	79.0 (56.0–90.0)	Alpha (dominant)
Lopez Bernal/UK	TNCC	9,682/171,834		GP	≥16	BNT162b2/ ChAdOx1	Symptomatic	21	48.7 (45.5–51.7)	14	87.5 (85.1–89.5)	Alpha
		7,812/120,761		GP	≥16	BNT162b2	Symptomatic	21	47.5 (41.6–52.8)	14	93.7 (91.6–95.3)	Alpha
		9,183/147,444		GP	≥16	ChAdOx1	Symptomatic	21	48.7 (45.2–51.9)	14	74.5 (68.4–79.4)	Alpha
Abu-Raddad/Qatar	TNCC	19,017/19,432		GP	33 (22-40) ¹	BNT162b2	All infections	0	29.5 (22.9–35.5)	14	89.5 (85.9–92.3)	Alpha
Bernal/UK	TNCC	3,034/9,487		Older	≥70	BNT162b2	Symptomatic	21	36.2 (23.7–46.6)	14	90.0 (84.0–94.0)	Alpha
Chemaitelly/Qatar	TNCC	23,904/23,951		GP	32 (25-39) ¹	mRNA-1273	All infections	14	88.1 (83.7–91.5)	14	100 (91.8–100)	Alpha
Charmet/France	Case-cont rol	31,313/3,644		GP	≥20	BNT162b2/ mRNA-1273	All infections	NA	NA	7	86.0 (81.0–90.0)	Alpha
Skowronski/Canada	TNCC	303/10,388		Older	≥70	BNT162b2/ mRNA-1273	All infections	21	67.0 (57.0–75.0)	NA	NA	Alpha
Sheikh/UK	TNCC	6,205/187,318		GP	NA	BNT162b2	All infections	28	38.0 (29.0–45.0)	14	92.0 (90.0–93.0)	Alpha
		6,884/203,579		GP	NA	ChAdOx1	All infections	28	37.0 (32.0–42.0)	14	73.0 (66.0–78.0)	Alpha
Carazo/Canada	TNCC	901/46,862		HCWs	18-74	BNT162b2/ mRNA-1273	All infections	14	60.0 (53.6–65.5)	7	92.6 (87.1–95.8)	Alpha

Chung/Canada	TNCC	12,582/259,986	GP	≥16	BNT162b2/ mRNA-1273	Symptomatic	14	61.0 (56.0–66.0)	7	90.0 (85.0–94.0)	Alpha
Chemaitelly/Qatar <i>_preprint</i>	TNCC	1,888/1,888	GP	32 (23-39) ¹	BNT162b2	All infections	14	54.9 (28.0–72.4)	0-4 weeks	67.8 (57.1–76.1)	Alpha
Nasreen/Canada <i>_preprint</i>	TNCC	368,323/51,540	GP	≥16	BNT162b2	Symptomatic	21	69.0 (67.0–71.0)	14	89.0 (87.0–91.0)	Alpha
			GP	≥16	mRNA-1273	Symptomatic	21	84.0 (80.0–86.0)	14	91.0 (84.0–95.0)	Alpha
			GP	≥16	ChAdOx1	Symptomatic	21	72.0 (68.0–76.0)	14	75.0 (-98.0–97.0)	Alpha

Abbreviations: VE, vaccine effectiveness; HCWs, healthcare workers; TNCC, test-negative case-control; GP, general population; Day_1, days after the 1st dose; Day_2, days after the 2nd dose; RCT, randomized controlled trial; CI, confidence interval.

¹ Median age (interquartile range)

Supplementary Table 5. VE of COVID-19 vaccines against B.1.351 (Beta) and P.1 (Gamma) variant

First author/Country	Study design	Vaccine/control Cases/controls	or	Participants	Age (years)	Vaccine	Outcomes	Day_1	VE% of one dose (95% CI)	Day_2	VE% of two doses (95% CI)	Variants
Shinde/South Africa	RCT	1,357/1,327		GP	18-84	NVX-CoV2373	Symptomatic	NA	NA	NA	51.1 (-0.6–76.2)	Beta
Madhi/South Africa	RCT	750/714		GP	18-65	ChAdOx1	Symptomatic	NA	NA	NA	10.4 (-76.8–54.8)	Beta
Sadoff/South Africa	RCT	2,473/2,496		GP	≥18	Ad26.COVS.S	Symptomatic	14	52.0 (30.3–67.4)	NA	NA	Beta
	RCT	2,473/2,496		GP	≥18	Ad26.COVS.S	Symptomatic	28	64.0 (41.2–78.7)	NA	NA	Beta
Thomas/South Africa <i>preprint</i>	RCT	291/276		GP	≥16	BNT162b2	All infections	NA	NA	7	100 (53.5–100)	Beta
Abu-Raddad/Qatar	TNCC	21,685/22,204		GP	33 (22-40) ¹	BNT162b2	All infections	0	16.9 (10.4–23.0)	14	75.0 (70.5–78.9)	Beta
Chemaitelly/Qatar	TNCC	48,297/48,456		GP	32 (25-39) ¹	mRNA-1273	All infections	14	61.3 (56.5–65.5)	14	96.4 (91.9–98.7)	Beta
Charmet/France	Case-control	2,550/3,644		GP	≥20	BNT162b2/ mRNA-1273	All infections	NA	NA	7	77.0 (63.0–86.0)	Beta (95.1%) Gamma (4.9%)
Lefèvre/France	Cohort	338/40		LTCH	89 (83-92) ¹	BNT162b2	All infections	14	55.0 (13.0–76.0)	7	49.0 (14.0–69.0)	Beta
Chemaitelly/Qatar <i>preprint</i>	TNCC	3,277/3,277		GP	32 (23-39) ¹	BNT162b2	All infections	14	26.1 (0.0-45.7)	0-4 weeks	74.3 (68.5-79.2)	Beta
Williams/Canada	Cohort	48/12		Residents of LTCH	NA	mRNA-1273	All infections	NA	NA	14	52.5 (26.9–69.1)	Gamma
		43/40		Staff of LTCH	NA	mRNA-1273	All infections	NA	NA	14	66.2 (2.3–88.3)	Gamma
Ranzani/Brazil	TNCC	26,433/17,622		Older	≥70	CoronaVac	Symptomatic	14	12.5 (3.7–20.6)	14	46.8 (38.7–53.8)	Gamma
Skowronski/Canada	TNCC	180/10,388		Older	≥70	BNT162b2/ mRNA-1273	All infections	21	61.0 (45.0–72.0)	NA	NA	Gamma
Hitchings/Brazil <i>preprint</i>	TNCC	418/418		HCWs	≥18	CoronaVac	Symptomatic	NA	NA	14	36.8 (-54.9–74.2)	Gamma (66%)
Chung/ Canada	TNCC	NA/259,986		GP	≥16	BNT162b2/ mRNA-1273	Symptomatic	14	43.0 (22.0–59.0)	7	88.0 (61.0–96.0)	Beta/Gamma

Nasreen/Canada_pre <i>print</i>	TNCC	3,005/351,540	GP	≥16	BNT162b2	Symptomatic	21	65.0 (56.0–71.0)	14	85.0 (70.0–93.0)	Beta/Gamma
			GP	≥16	mRNA-1273	Symptomatic	21	78.0 (60.0–88.0)	NA	NA	Beta/Gamma
			GP	≥16	ChAdOx1	Symptomatic	21	50.0 (27.0–66.0)	NA	NA	Beta/Gamma

Abbreviations: VE, vaccine effectiveness; HCWs, healthcare workers; TNCC, test-negative case-control; LTCH, long term care homes; GP, general population; Day_1, days after the 1st dose; Day_2, days after the 2nd dose; RCT, randomized controlled trial; CI, confidence interval.

¹ Median age (interquartile range)

Supplementary Table 6. VE of COVID-19 vaccines against B.1.617.2 (Delta) variant

First author/ Country	Study design	Vaccine/control Cases/controls	or	Participants	Age (years)	Vaccine	Outcomes	Day_1	VE% of one dose (95% CI)	Day_2	VE% of two doses (95% CI)	Variants
Ella/India/_preprint	RCT	8,471/8,502		GP	18-98	BBV152	Symptomatic	NA	NA	14	65.2 (33.1–83.0)	Delta
Lopez Bernal/UK	TNCC	5,876/171,834		GP	≥16	BNT162b2/ ChAdOx1	Symptomatic	21	30.7 (25.2–35.7)	14	79.6 (76.7–82.1)	Delta
		4,302/120,761		GP	≥16	BNT162b2	Symptomatic	21	35.6 (22.7–46.4)	14	88.0 (85.3–90.1)	Delta
		5,617/147,444		GP	≥16	ChAdOx1	Symptomatic	21	30.0 (24.3–35.3)	14	67.0 (61.3–71.8)	Delta
Li/China	TNCC	74/292		GP	18-59	CoronaVac/ CNBG	All infections	14	13.8 (-60.2–54.8)	14	59.0 (16.0–81.6)	Delta
Nanduri/US	Cohort	5,011,746/953,861		Nursing home	NA	BNT162b2/ mRNA-1273	All infections	NA	NA	14	53.1 (49.1–56.7)	Delta
		3,248,732/953,861			NA	BNT162b2	All infections	NA	NA	14	52.4 (48.0–56.4)	Delta
		1,763,014/953,861			NA	mRNA-1273	All infections	NA	NA	14	50.6 (45.0–55.7)	Delta
Fowlkes/US	Cohort	2,352/488		Frontline workers	NA	mRNA-1273/ BNT162b2	All infections	NA	NA	14	66.0 (26.0–84.0)	Delta
Sheikh/UK	TNCC	4,043/185,156		GP	NA	BNT162b2	All infections	28	30.0 (17.0–41.0)	14	79.0 (75.0–82.0)	Delta
		4,679/201,374		GP	NA	ChAdOx1	All infections	28	18.0 (9.0–25.0)	14	60.0 (53.0–66.0)	Delta
Puranik/US_preprint	Cohort	21,079/24,444		GP	≥18	mRNA-1273	All infections	NA	NA	14	76.0 (58.0–87.0)	Delta (70%)
		21,946/24,444		GP	≥18	BNT162b2	All infections	NA	NA	14	42.0 (13.0–62.0)	Delta (70%)
Chemaitelly/Qatar _preprint	TNCC	1,935/1,935		GP	32 (23-39)	BNT162b2	All infections	14	67.4 (46.3–80.9)	0-4 weeks	83.8 (73.6–90.5)	Delta
Nasreen/Canada _preprint	TNCC	991/351,540		GP	≥16	BNT162b2	Symptomatic	21	61.0 (51.0–70.0)	14	85.0 (59.0–94.0)	Delta
				GP	≥16	mRNA-1273	Symptomatic	21	70.0 (52.0–81.0)	NA	NA	Delta
				GP	≥16	ChAdOx1	Symptomatic	21	70.0 (46.0–83.0)	NA	NA	Delta
Tang/Qatar	TNCC	1,959/1,959		GP	31 (24-37)	BNT162b2/	All infections	14	70.5 (55.2–80.6)	14	63.3 (55.7–69.6)	Delta

<i>_preprint</i>					mRNA-1273						
		1,830/1,830	GP	31 (24-37)	BNT162b2	All infections	14	65.5 (40.9–79.9)	14	59.6 (50.7–66.9)	Delta
		1,666/1,666	GP	31 (24-37)	mRNA-1273	All infections	14	79.7 (60.8–89.5)	14	86.1 (78.0–91.3)	Delta
Pramod/India	TNCC	360/360	HCWs	34 (28-43)	ChAdOx1-S	All infections	21	49.0 (17.0–68.0)	14	54.0 (27.0–71.0)	Delta
<i>_preprint</i>											
Pouwels/UK	Cohort	358,983 (total)	GP	≥18	BNT162b2	All infections	21	57.0 (50.0–63.0)	14	80.0 (77.0–83.0)	Delta
<i>_preprint</i>											(dominant)
			GP	≥18	ChAdOx1	All infections	21	46.0 (35.0–55.0)	14	67.0 (62.0–71.0)	Delta
			GP	18–64	mRNA-1273	All infections	21	75.0 (64.0–83.0)	NA	NA	Delta

Abbreviations: VE, vaccine effectiveness; HCWs, healthcare workers; TNCC, test-negative case-control; LTCH, long term care homes; GP, general population; Day_1, days after the 1st dose; Day_2, days after the 2nd dose; RCT, randomized controlled trial; CI, confidence interval.

¹ Median age (interquartile range)